WHITE BEAR LAKE, MN - Envoy Medical®, Inc. (NASDAQ: COCH), a medical device company with a market capitalization of $35.64 million, has announced a significant milestone in their clinical trial for the fully implanted Acclaim® cochlear implant, with successful activation of the device in all 10 participants in the initial phase of the study. The announcement has contributed to the company’s strong recent performance, with InvestingPro data showing a 10.63% return over the past week. Brent Lucas, CEO of the company, expressed optimism about the progress and anticipates moving into the final stage of the trial by the fourth quarter of this year.
The Acclaim Cochlear Implant, which received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019, is considered to be a first-of-its-kind hearing device. It is designed to assist those with severe to profound sensorineural hearing loss, a condition not sufficiently managed by traditional hearing aids. Unlike conventional implants, the Acclaim CI uses a sensor that takes advantage of the ear’s natural anatomy to capture sound, potentially offering a new solution for adults who qualify for the device. According to InvestingPro analysis, analysts have set price targets ranging from $5.00 to $9.25, reflecting potential confidence in the technology’s market prospects.
This milestone is part of a broader effort by Envoy Medical to meet what they believe is a significant demand for fully implanted cochlear implants. The company also highlighted the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI), the only FDA-approved fully implanted hearing device for certain types of hearing loss, which operates without external components and provides continuous hearing through the ear’s natural structure.
The press release emphasized the investigational status of the Acclaim Cochlear Implant, which is currently limited by federal law to investigational use. Envoy Medical’s statements about the potential of the Acclaim CI and the interest from individuals with hearing loss are forward-looking and subject to risks and uncertainties that could affect the actual outcomes and future events. InvestingPro data indicates some financial challenges, with the company’s overall Financial Health Score rated as WEAK (1.46/5) and significant cash burn concerns. Investors can access over 10 additional ProTips and comprehensive financial metrics with an InvestingPro subscription.
The company’s press release also contained forward-looking statements regarding its business outlook, the clinical trial process, and the market acceptance of the Acclaim CI. These statements are based on current expectations and involve risks and uncertainties, which are detailed in the company’s filings with the SEC, including its Annual Report on Form 10-K filed on March 31, 2025.
Investors and the public are reminded that this news is based on a press release statement from Envoy Medical and should consider the information in the context of the company’s regulatory filings and the inherent uncertainties of the medical device industry.
In other recent news, Envoy Medical, Inc. has expanded its patent portfolio with new patents issued in the United States, Japan, and Hong Kong. The U.S. Patent & Trademark Office granted two patents for implantable cochlear systems, while the Japanese Patent Office awarded three patents related to cochlear implant systems. Additionally, Envoy Medical received a patent from the Hong Kong Patent Office concerning cochlear implant accessories. Meanwhile, the company faces a potential delisting from The Nasdaq Stock Market due to not meeting the minimum market value requirement of $35 million for 31 consecutive days. Nasdaq has given Envoy Medical 180 days to regain compliance, requiring the company to achieve the necessary market value for ten consecutive business days before late August 2025. Furthermore, Envoy Medical has announced its Annual Meeting of Stockholders, scheduled for May 28, 2025, in Vadnais Heights, Minnesota. Shareholders of record as of April 8, 2025, will be eligible to vote, and the company has set a deadline for shareholder proposals and director nominations. These developments reflect Envoy Medical’s ongoing activities in the medical device industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.